DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ENABLEX

Summary for Tradename: ENABLEX

Patents:2
Applicants:1
NDAs:1
Suppliers: see list3
drug
patent expirations by year for
 ENABLEX

Pharmacology for Tradename: ENABLEX

Clinical Trials for: ENABLEX

2 Week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Yrs) With Neurogenic Detrusor Overactivity
Status: Terminated Condition: Neurogenic Detrusor Overactivity

Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women
Status: Active, not recruiting Condition: Overactive Bladder

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
Status: Completed Condition: Healthy

Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers.
Status: Not yet recruiting Condition: Bioequivalency

Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.
Status: Not yet recruiting Condition: Bioequivalency

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
Status: Completed Condition: Healthy

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
Status: Completed Condition: Overactive Bladder (OAB)

Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain
Status: Recruiting Condition: Bladder Spasms; Ureteral Stent Pain; Postoperative

Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
Status: Completed Condition: Healthy Volunteers

Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
Status: Completed Condition: Overactive Bladder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Warner Chilcott Llc
ENABLEX
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL021513Dec 22, 2004RXNo5,096,890<disabled>YY<disabled>
Warner Chilcott Llc
ENABLEX
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL021513Dec 22, 2004RXNo6,106,864<disabled>Y<disabled>
Warner Chilcott Llc
ENABLEX
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL021513Dec 22, 2004RXYes5,096,890<disabled>YY<disabled>
Warner Chilcott Llc
ENABLEX
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL021513Dec 22, 2004RXYes6,106,864<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ENABLEX

Drugname Dosage Strength RLD Submissiondate
darifenacin hydrobromideExtended-release Tablets7.5 mg and 15 mgEnablex12/22/2008

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc